In This Article:
As the U.S. stock market experiences fluctuations ahead of major earnings reports, investors are keenly observing opportunities across various sectors. Penny stocks, a term that may seem outdated, still represent an intriguing segment for those interested in smaller or newer companies. By focusing on penny stocks with solid financial foundations and growth potential, investors can find opportunities that offer both value and stability amidst current market conditions.
Top 10 Penny Stocks In The United States
Name | Share Price | Market Cap | Financial Health Rating |
BAB (OTCPK:BABB) | $0.827 | $6.01M | ★★★★★★ |
QuantaSing Group (NasdaqGM:QSG) | $3.08 | $144.65M | ★★★★★★ |
Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $69.71M | ★★★★★★ |
PHX Minerals (NYSE:PHX) | $3.56 | $133.43M | ★★★★★☆ |
So-Young International (NasdaqGM:SY) | $1.25 | $90.8M | ★★★★☆☆ |
ZTEST Electronics (OTCPK:ZTST.F) | $0.27 | $9.77M | ★★★★★★ |
Puma Biotechnology (NasdaqGS:PBYI) | $2.74 | $134.5M | ★★★★★★ |
Better Choice (NYSEAM:BTTR) | $1.63 | $2.97M | ★★★★★★ |
Zynerba Pharmaceuticals (NasdaqCM:ZYNE) | $1.30 | $65.6M | ★★★★★☆ |
CBAK Energy Technology (NasdaqCM:CBAT) | $0.8799 | $79.14M | ★★★★★☆ |
Click here to see the full list of 738 stocks from our US Penny Stocks screener.
We're going to check out a few of the best picks from our screener tool.
X4 Pharmaceuticals
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: X4 Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics for rare diseases, with a market cap of $62.76 million.
Operations: X4 Pharmaceuticals, Inc. has not reported any revenue segments.
Market Cap: $62.76M
X4 Pharmaceuticals, Inc., with a market cap of US$62.76 million, is pre-revenue and has faced increasing losses over the past five years. Recently, the company reported a net loss of US$36.7 million for Q3 2024 but showed positive clinical trial results for mavorixafor in treating chronic neutropenia. Despite its unprofitability and high debt-to-equity ratio of 126.2%, X4's short-term assets exceed both its short- and long-term liabilities, providing some financial stability. However, its cash runway is less than a year if free cash flow continues to decline at historical rates.
-
Take a closer look at X4 Pharmaceuticals' potential here in our financial health report.
-
Assess X4 Pharmaceuticals' future earnings estimates with our detailed growth reports.
Acacia Research
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Acacia Research Corporation specializes in acquiring and managing companies within the technology, energy, and industrial sectors, with a market cap of $430.37 million.